Workflow
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?
诺华诺华(US:NVS) ZACKS·2025-07-15 22:51

Key Takeaways NVS is set to report Q2 earnings on July 17, 2025. Entresto, Kisqali, and Kesimpta sales likely drove growth amid expanding demand and new indications. NVS recently acquired Regulus Therapeutics for 0.8Bupfronttoaddfarabursentoitspipeline.NovartisAG(NVS),aSwisspharmagiant,isscheduledtoreportsecond−quarter2025resultsonJuly17.TheZacksConsensusEstimateforrevenuesispeggedat0.8B upfront to add farabursen to its pipeline.Novartis AG (NVS) , a Swiss pharma giant, is scheduled to report second-quarter 2025 results on July 17.The Zacks Consensus Estimate for revenues is pegged at 14.04 billion, while the same for earnings is pinned at $2.38 per share. (Find the latest ...